Whether you are a researcher comparing vendors or someone trying to understand this peptide before it reaches pharmacies, everything you need is here
Arrowhead Pharmaceuticals requests regulatory clearance to initiate phase 1/2a study of ARO-ALK7 for the treatment of obesity
The phase 3 TRIUMPH-4 trial recently reported average weight loss of up to 71.2 pounds
Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases
In most cultures, food is associated with a wide range of feelings, including reward, celebration, pleasure, boredom, and more
While $500 to $700 monthly represents a significant expense, it compares favorably to the healthcare costs of poorly controlled diabetes, cardiovascular disease, or repeated joint surgeries that obesity promotes